Skip to main content

Table 3 Pulmonary function tests, chest X-ray, HRCT, and origin of pathologies in HRCT, differentiated regarding the ILD group and non-ILD group

From: Assessing the diagnostic value of a potential screening tool for detecting early interstitial lung disease at the onset of inflammatory rheumatic diseases

Variable ILD group, number (%) Non-ILD group, number (%) Difference
Number 63 (50.0%) 63 (50.0%)  
PFT 61 (96.8%) 61 (96.8%) χ2(1) = 0.000,P = 1.000
Median ± SD
 DLCO 59.4 ± 19.6% 79.9 ± 18.3% t(118) = 5.91,P < 0.001
 TLC 84.4 ± 19.8% 98.5 ± 12.9% t(95) = 4.47,P < 0.001
 FVC 82.3 ± 21.3% 92.6 ± 17.9% t(118) = 2.89,P = 0.005
 FEV1 82.0 ± 23.4% 92.2 ± 16.6% t(104) = 2.78,P = 0.007
 TLCO 75.0 ± 19.6% 88.1 ± 17.3% t(116) = 3.84,P < 0.001
Chest X-ray 53 (84.1%) 53 (84.1%) χ2(1) = 0.000,P = 1.000
HRCT 63 (100.0%) 38 (60.3%) χ2(1) = 43.955,P < 0.001
Origin of the pathologies in HRCT
 ILD in IRD 63 (100.0%) 0 (0.0%) χ2(4) = 80.000,P < 0.001
 Respiratory bronchiolitis ILD 0 (0.0%) 7 (11.1%)
 Post-inflammatory change 0 (0.0%) 6 (9.5%)
 Other lung diseases 0 (0.0%) 2 (3.2%)
  1. DLCO Diffusing capacity for carbon monoxide, FEV1 Forced expiratory volume in 1 s, FVC Forced vital capacity, HRCT High-resolution computed tomography, LR Likelihood ratio, PFT Pulmonary function tests, TLC Total lung capacity, TLCO Transfer factor of the lung for carbon monoxide